Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) shares reached a new 52-week high on Friday . The stock traded as high as $8.28 and last traded at $8.24, with a volume of 2027354 shares traded. The stock had previously closed at $8.10.
Wall Street Analysts Forecast Growth
RGLS has been the topic of several recent research reports. Canaccord Genuity Group reissued a "hold" rating and issued a $11.00 price target (down previously from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a report on Friday, March 14th. Leerink Partnrs cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Jones Trading reiterated a "hold" rating and set a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Wall Street Zen began coverage on Regulus Therapeutics in a research report on Sunday, May 18th. They issued a "sell" rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.50.
Get Our Latest Research Report on RGLS
Regulus Therapeutics Trading Up 1.5%
The business's fifty day moving average price is $5.23 and its two-hundred day moving average price is $2.72. The firm has a market cap of $569.45 million, a P/E ratio of -7.69 and a beta of 0.35.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14. Research analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.
Insider Activity at Regulus Therapeutics
In related news, insider Preston Klassen bought 12,000 shares of Regulus Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The stock was acquired at an average price of $7.99 per share, for a total transaction of $95,880.00. Following the completion of the purchase, the insider now owns 48,055 shares in the company, valued at approximately $383,959.45. This represents a 33.28% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.35% of the stock is currently owned by company insiders.
Institutional Trading of Regulus Therapeutics
Hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Regulus Therapeutics by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 1,644 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Regulus Therapeutics in the 1st quarter valued at $120,000. Baker BROS. Advisors LP bought a new position in shares of Regulus Therapeutics during the 1st quarter worth about $4,715,000. Velan Capital Investment Management LP boosted its position in shares of Regulus Therapeutics by 14.3% during the 1st quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Driehaus Capital Management LLC bought a new stake in Regulus Therapeutics in the first quarter valued at about $1,677,000. Institutional investors own 92.38% of the company's stock.
About Regulus Therapeutics
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
